Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given an average rating of “Moderate Buy” by the eleven analysts that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $128.91.

A number of analysts have issued reports on the stock. Piper Sandler reiterated an “overweight” rating on shares of Oruka Therapeutics in a report on Wednesday, October 7th. Wall Street Zen downgraded shares of Oruka Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, August 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Tuesday. Wedbush set a $120.00 price objective on Oruka Therapeutics in a research report on Thursday, September 24th. Finally, UBS Group lifted their target price on Oruka Therapeutics from $100.00 to $130.00 and gave the stock a “buy” rating in a report on Wednesday, July 1st.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $76.68 on Thursday. The firm has a market cap of $5.08 billion, a P/E ratio of -37.77 and a beta of -0.37. Oruka Therapeutics has a 1 year low of $25.11 and a 1 year high of $115.51. The company has a 50 day simple moving average of $93.48 and a two-hundred day simple moving average of $79.88.

Oruka Therapeutics (NASDAQ:ORKA) last released its earnings results on Monday, August 10th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, sell-side analysts anticipate that Oruka Therapeutics will post -2.42 earnings per share for the current year.

Insiders Place Their Bets

In other Oruka Therapeutics news, CEO Lawrence Klein sold 25,000 shares of Oruka Therapeutics stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $83.62, for a total value of $2,090,500.00. Following the sale, the chief executive officer owned 923,128 shares of the company’s stock, valued at $77,191,963.36. The trade was a 2.64% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the company’s stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $80.60, for a total value of $805,919.40. Following the sale, the senior vice president directly owned 14,219 shares in the company, valued at $1,146,051.40. This trade represents a 41.29% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 147,950 shares of company stock valued at $13,579,010 in the last quarter. 23.49% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Oruka Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Sei Investments Co. boosted its holdings in shares of Oruka Therapeutics by 136.0% in the 1st quarter. Sei Investments Co. now owns 22,840 shares of the company’s stock worth $1,120,000 after purchasing an additional 13,164 shares during the period. Legal & General Group Plc bought a new position in shares of Oruka Therapeutics during the 2nd quarter valued at approximately $2,874,000. Dimensional Fund Advisors LP bought a new position in shares of Oruka Therapeutics during the 1st quarter valued at approximately $5,543,000. Handelsbanken Fonder AB purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at $15,313,000. Finally, Palo Alto Investors LP purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at $3,192,573. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company’s approach is designed to extend the duration of treatment and potentially reduce the frequency of dosing for patients with chronic inflammatory conditions.

Oruka’s pipeline includes ORKA-001 and ORKA-002, next-generation monoclonal antibodies targeting interleukin-23 (IL-23), a cytokine involved in several autoimmune and inflammatory diseases.